List of resources for families with infants in the Neonatal Intensive Care Unit.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
This hotline will offer a range of support, including brief interventions, referrals to both community-based and telehealth providers as needed.
This preliminary study suggests that web-based interventions with coaching are feasible, acceptable, and potentially effective treatment options for women with mild to moderate postpartum depression and/or anxiety.
In this randomized controlled trial, a CBT-based workshop for women with PPD led to clinically meaningful reductions in depression and anxiety.
Postpartum psychosis is the most severe form of postpartum psychiatric illness. What are the signs and symptoms?
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
May 4, 2022 is World Maternal Mental Health Day, coming together to increase awareness of perinatal mood and anxiety disorders.